Celebrated Christian author and famed theologian Tim Keller died at the age of 72 on May 19 following a fight with pancreatic cancer, as reported by his church. The best-selling Christian author, who is also the founding pastor of New York City’s Redeemer Presbyterian Church, was first diagnosed with stage four pancreatic cancer in 2020.
Fox News reports:
Best-selling Christian author and noted theologian Tim Keller has passed away Friday following a battle with pancreatic cancer, his church says.
Keller, the founding pastor of Redeemer Presbyterian Church in New York City, was initially diagnosed with stage four pancreatic cancer in May 2020.
“It is with a heavy heart that I write today to inform you that Redeemer Presbyterian Church founder and long-time senior pastor, Tim Keller, passed away this morning at age 72, trusting in the sure and certain hope of the resurrection,” Bruce Terrell said on behalf of the Redeemer Network Leadership Team. “We are forever grateful for his leadership, heart, and dedication to sharing the love of Christ with others.
“While we will miss his presence here, we know he is rejoicing with his Savior in heaven,” he added.
Following his 2020 diagnosis, Keller underwent two years of chemotherapy and participated in an immunotherapy drug trial at Maryland’s National Institute for Health in Bethesda until January. Despite the immunotherapy effectively eliminating 99% of the cancerous tumors, in March, Keller revealed in a Facebook post the recurrence of additional cancerous tumors, necessitating a modified version of the previous immunotherapy treatment.
Since Keller’s 2020 diagnosis, he has undergone two years of chemotherapy. He was also participating in the immunotherapy drug trial at the National Institute for Health in Bethesda, Maryland as recently as January.
However, despite the immunotherapy successfully killing 99% of the cancerous tumors, Keller announced in a Facebook post in March the return of additional cancerous tumors requiring him to undergo a variation of the previous immunotherapy treatment.
“They are unfortunately in some fairly inconvenient places, so the doctors encouraged us to go through the treatment again, this time targeting a different genetic marker of cancer,” Keller wrote.
Read the full article here.